300015 爱尔眼科
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入11,945,7053.81%22,352,60520,982,89420,367,15716,109,947
减:营业总成本9,126,9254.19%17,711,12616,628,94215,113,23312,152,478
    其中:营业成本6,436,6258.74%11,821,51210,886,54910,021,9757,980,389
               财务费用162,305237.26%175,995214,29873,6286,655
               资产减值损失(1,671)153.50%(157,139)(187,757)(383,606)(95,464)
公允价值变动收益(21,199)-162.50%98,290334,398(79,423)(356,890)
投资收益24,100227.31%75,143213,22046,52343,910
    其中:对联营企业和合营企业的投资收益(2,461)--338----(3)
营业利润2,820,5593.33%4,603,0954,824,9174,947,9473,534,500
利润总额2,596,077-2.51%4,425,1354,594,2824,551,0193,335,056
减:所得税费用1,052,882137.50%951,916858,153895,023646,059
净利润1,543,195-30.48%3,473,2193,736,1303,655,9962,688,997
减:非控股权益186,16810.35%232,960180,074297,124164,766
股东净利润1,357,026-33.83%3,240,2593,556,0563,358,8722,524,231

市场价值指针
每股收益 (元) *0.146-34.02%0.3500.3850.3640.279
每股派息 (元) *----0.1800.1600.1500.100
每股净资产 (元) *2.4696.21%2.3562.2212.0212.323
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容